Abstract
Objective: Goodman and Gilmans The Pharmacological Basis of Therapeutics (GGPBT) has been a cornerstone in the education of pharmacists, physicians, and pharmacologists for decades. The objectives of this report were to describe and evaluate the 13th edition of GGPBT including 1) author characteristics; 2) recency of citations; 3) conflict of interest (CoI) disclosure, and 4) expert evaluation of chapters. Methods: Contributors (N = 115) sex, professional degrees, and presence of undisclosed potential CoI as reported by the Center for Medicare and Medicaids Open Payments (2013 to 2017) were examined. Year of publication of citations were extracted relative to comparison textbooks (Katzungs Basic and Clinical Pharmacology (KatBCP) and DiPiros Pharmacotherapy: A Pathophysiologic Approach (DiPPAPA). Content experts in pharmacy and pharmacology education provided chapter reviews. Results: The percent of GGPBT contributors that were female (20.9%) was equivalent to those in KatBCP (17.0%). Citations in GGPBT (11.5 + 0.2 years) were significantly older than those in KatBCP (10.4 + 0.2) and DiPPAPA (9.1 + 0.1, p < .0001). Contributors to GGPBT received three million in undisclosed remuneration from pharmaceutical companies (Maximum author = $743,718). In contrast, DiPPAPA made CoI information available. However, self-reported disclosures were not uniformly congruent with Open Payments reported data. Reviewers noted several strengths but also some areas for improvement. Conclusion: GGPBT will continue to be an important component of the biomedical curriculum. Areas of improvement include more diverse authorship, improved conflict of interest transparency, and greater inclusion of more recent citations.
Competing Interest Statement
BJP is supported by the Center of Excellence, Health Resources Services Administration (D34HP31025) and Pfizer. DYK is currently employed with a biotechnology company. The other authors have no disclosures.
Funding Statement
This endeavor was completed using software provided by the Husson University School of Pharmacy and the National Institute of Environmental Health Sciences (T32 ES007060-31A1). No external funding was received to support this study.
Author Declarations
All relevant ethical guidelines have been followed and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Not Applicable
Any clinical trials involved have been registered with an ICMJE-approved registry such as ClinicalTrials.gov and the trial ID is included in the manuscript.
Not Applicable
I have followed all appropriate research reporting guidelines and uploaded the relevant Equator, ICMJE or other checklist(s) as supplementary files, if applicable.
Not Applicable
Data Availability
The raw data in Figure 1 is included as a supplemental file.
